Inflammatory markers related to survival in breast cancer patients: Peru.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS
Jhony Alberto De La Cruz-Vargas, Luis Roldán-Arbieto, Robert Malpartida Palomino, Diana Ferrer Ponce, Cesar Fernández Anccas, Lucy Correa López, Brady Ernesto Beltrán Gárate, José Manuel Vela Ruiz
{"title":"Inflammatory markers related to survival in breast cancer patients: Peru.","authors":"Jhony Alberto De La Cruz-Vargas, Luis Roldán-Arbieto, Robert Malpartida Palomino, Diana Ferrer Ponce, Cesar Fernández Anccas, Lucy Correa López, Brady Ernesto Beltrán Gárate, José Manuel Vela Ruiz","doi":"10.1177/03936155241283480","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer is a disease with high global prevalence. Clinical inflammatory biomarkers have been proposed as prognostic indicators in oncology. This research aims to determine the relationship between inflammatory markers and overall survival in breast cancer patients from four representative hospitals in Lima, Peru.</p><p><strong>Methods: </strong>This is a multicentric, analytical, longitudinal retrospective cohort study with survival analysis in female patients with breast cancer, from 2015 to 2020, who had received at least one complete treatment regimen. The dependent variable was overall survival, and the independent variables were inflammatory markers neutrophil lymphocyte ratio, platelet lymphocyte ratio (PLR), albumin, and red cell distribution width; intervening variables included age, clinical stage, molecular subtype, and other known prognostic factors. The Kaplan-Meier method was applied to generate survival curves with the Log-Rank test, and finally, Cox regression, to find crude and adjusted hazard ratios (HR).</p><p><strong>Results: </strong>Of 705 evaluated patients, 618 were analyzed. The mean age was 56.6 ± 12.3 years, 18.0% of patients were pure HER2 positive, 39.3% luminal A, 29.9% luminal B, 11.0% triple-negative, and 81.4% showed overweight and obesity. The average overall survival was 51.1 months. In the multivariate analysis, factors significantly related to lower overall survival were PLR > 150 (adjusted HR: 2.33; 95% confidence interval (CI): 1.22, 4.44) and stage III (adjusted HR: 4.15; 95% CI: 1.35, 12.83).</p><p><strong>Conclusions: </strong>The Elevated Platelet-Lymphocyte Index and advanced clinical stage were associated with lower overall survival in breast cancer patients. Furthermore, PLR >150 proved to be an independent prognostic factor for mortality.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03936155241283480","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Breast cancer is a disease with high global prevalence. Clinical inflammatory biomarkers have been proposed as prognostic indicators in oncology. This research aims to determine the relationship between inflammatory markers and overall survival in breast cancer patients from four representative hospitals in Lima, Peru.

Methods: This is a multicentric, analytical, longitudinal retrospective cohort study with survival analysis in female patients with breast cancer, from 2015 to 2020, who had received at least one complete treatment regimen. The dependent variable was overall survival, and the independent variables were inflammatory markers neutrophil lymphocyte ratio, platelet lymphocyte ratio (PLR), albumin, and red cell distribution width; intervening variables included age, clinical stage, molecular subtype, and other known prognostic factors. The Kaplan-Meier method was applied to generate survival curves with the Log-Rank test, and finally, Cox regression, to find crude and adjusted hazard ratios (HR).

Results: Of 705 evaluated patients, 618 were analyzed. The mean age was 56.6 ± 12.3 years, 18.0% of patients were pure HER2 positive, 39.3% luminal A, 29.9% luminal B, 11.0% triple-negative, and 81.4% showed overweight and obesity. The average overall survival was 51.1 months. In the multivariate analysis, factors significantly related to lower overall survival were PLR > 150 (adjusted HR: 2.33; 95% confidence interval (CI): 1.22, 4.44) and stage III (adjusted HR: 4.15; 95% CI: 1.35, 12.83).

Conclusions: The Elevated Platelet-Lymphocyte Index and advanced clinical stage were associated with lower overall survival in breast cancer patients. Furthermore, PLR >150 proved to be an independent prognostic factor for mortality.

与乳腺癌患者存活率有关的炎症指标:秘鲁
导言乳腺癌是一种全球发病率很高的疾病。临床炎症生物标志物被认为是肿瘤学的预后指标。本研究旨在确定秘鲁利马四家代表性医院乳腺癌患者的炎症标志物与总生存期之间的关系:这是一项多中心、分析性、纵向回顾性队列研究,对2015年至2020年期间至少接受过一次完整治疗方案的女性乳腺癌患者进行生存分析。因变量为总生存期,自变量为炎症指标中性粒细胞淋巴细胞比值、血小板淋巴细胞比值(PLR)、白蛋白和红细胞分布宽度;干预变量包括年龄、临床分期、分子亚型和其他已知预后因素。采用 Kaplan-Meier 法生成生存曲线,并进行 Log-Rank 检验,最后采用 Cox 回归法计算粗略和调整后的危险比(HR):在 705 名接受评估的患者中,有 618 人接受了分析。平均年龄为(56.6 ± 12.3)岁,18.0%的患者为纯 HER2 阳性,39.3%为管腔 A 型,29.9%为管腔 B 型,11.0%为三阴性,81.4%为超重和肥胖。平均总生存期为 51.1 个月。在多变量分析中,PLR>150(调整后HR:2.33;95%置信区间(CI):1.22,4.44)和III期(调整后HR:4.15;95%置信区间(CI):1.35,12.83)与较低的总生存率显著相关:血小板淋巴细胞指数升高和晚期临床分期与乳腺癌患者较低的总生存率有关。结论:血小板淋巴细胞指数升高和晚期临床分期与乳腺癌患者较低的总生存率有关,此外,PLR > 150 被证明是死亡率的独立预后因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信